The biotech sector has endured many ups and downs over the last few years, and recent headwinds like tariffs, industry shakeups, and fierce global competition are forcing the sector to hit the reset button on strategies that will successfully attract the attention of VCs.

Thank you to Melanie Senior for shining a light on the challenges facing the biotech VC space, and for including Avidicure in your reporting. We are proud to have secured one of the largest seed rounds in 2025 for our next-generation antibody platform, as these funds will further our goal of bringing our lead oncology product, AVC-S-101, into clinical development for solid tumors.

You can read the full report in Nature Biotechnology here: https://bit.ly/4nreDeS